3-Hydroxyphencyclidine (3-HPC), a derivative of phencyclidine (PCP), is growing attracting clinical scrutiny due to limited data suggesting different pharmacological actions. Current research suggest that 3-HPC may exhibit distinct impacts on the central nervous system, arguably influencing to some of the unanticipated symptoms associated with PCP